ALK plus advanced NSCLC New ALK Inhibitor extends Sequence Options

被引：0
|
作者：
Freye, Reimund
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷 / 11期
关键词：
D O I：
10.1159/000494601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：720 / 720
页数：1
相关论文
共 50 条
  • [31] Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
    Zhu, Qian
    Hu, Hao
    Weng, De-Sheng
    Zhang, Xiao-Fei
    Chen, Chang-Long
    Zhou, Zi-Qi
    Tang, Yan
    Xia, Jian-Chuan
    BMC CANCER, 2017, 17
  • [32] Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
    Qian Zhu
    Hao Hu
    De-Sheng Weng
    Xiao-Fei Zhang
    Chang-Long Chen
    Zi-Qi Zhou
    Yan Tang
    Jian-Chuan Xia
    BMC Cancer, 17
  • [33] Advanced ALK plus NSCLC Third-generation Tyrosine Kinase Inhibitor available for First-line Use
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
  • [34] Native and rearranged ALK copy number and rearranged ALK cell count in NSCLC: Implications for ALK inhibitor therapy.
    Camidge, D. Ross
    Skokan, Margaret
    Kiatsimkul, Porntip
    Helfrich, Barbara
    Schulte, Nathan
    Maxson, DeLee
    Aisner, Dara L.
    Franklin, Wilbur A.
    Doebele, Robert Charles
    Varella-Garcia, Marileila
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Treatment beyond disease progression: ALK inhibitors in ALK-rearranged advanced NSCLC
    Leighl, N. B.
    Kuo, J.
    Pavel, A.
    Prescilla, M.
    Shepherd, F. A.
    Liu, G.
    Bradbury, P.
    Moskovits, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] G-BA Additional Benefit Assessment: Brigatinib (ALUNBRIG®) is the only ALK Inhibitor with substantial Additional Benefit in ALK plus NSCLC
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (12)
  • [37] Updated Data from JP28927 Study of Alectinib in ALK plus NSCLC Patients with or without History of ALK Inhibitor Treatment
    Hotta, Katsuyuki
    Hida, Toyoaki
    Nakagawa, Kazuhiko
    Seto, Takashi
    Satouchi, Miyako
    Nishio, Makoto
    Murakami, Haruyasu
    Ohe, Yuichiro
    Takeda, Koji
    Yoshimoto, Takuya
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S648 - S648
  • [38] Resensitizing Refractory ALK plus NSCLC: A Case Study
    Poh, Alissa
    CANCER DISCOVERY, 2016, 6 (03) : 220 - +
  • [39] PHASE I STUDY OF THE ALK INHIBITOR LDK378 IN JAPANESE PATIENTS WITH ADVANCED, ALK-REARRANGED NSCLC AND OTHER TUMORS HARBORING GENETIC ALK ALTERATIONS
    Seto, Takashi
    Murakami, Haruyasu
    Hirai, Fumihiko
    Horiike, Atsushi
    Takahashi, Toshiaki
    Suenaga, Naoko
    Tajima, Takeshi
    Tokushige, Kota
    Boral, Anthony
    Robson, Matthew
    Nishio, Makoto
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S595 - S596
  • [40] Real-World Treatment Patterns and Effectiveness in Patients with ALK plus Advanced NSCLC Treated with 1L ALK TKIs
    Chen, Y.
    Lin, H. M.
    Wan, Y.
    Yin, Y.
    Wu, Y.
    Hernandez, L.
    Danes, C.
    Churchill, E. N.
    Dimou, A.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S641 - S641
12345